Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1635 1636 1637 1658 1699 3794
This examiner grants 58% of resolved cases
Tiffany Nicole Grooms is an examiner in Tech Center 3700 and Art Unit 1635. Across 185 resolved cases, the data shows an allowance rate of 57.8 percent. This 57.8 percent figure provides a baseline for practitioners to understand the probability of a grant. The 185 resolved cases offer a look at the examiner's historical tendencies in this mechanical engineering and manufacturing center.
The data reveals an interview lift of 46.3 percent. This 46.3 percent lift indicates that an interview is associated with a higher likelihood of allowance compared to the baseline of cases where no interview is conducted. Practitioners may use this metric to evaluate the impact of verbal advocacy. This comparison is a key element of the prosecution strategy for cases in Art Unit 1635.
The median days to allowance for Grooms is 1289. This 1289-day period serves as a benchmark for the expected duration of successful prosecutions. The combination of the 57.8 percent allowance rate and the 46.3 percent interview lift, within the context of Tech Center 3700, helps in setting expectations for both timing and results.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18197948 | OPTIMIZED SIRNA SCAFFOLDS | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18140908 | SELECTIVE RNA-MODULATING AGENTS | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18658840 | YEAST STRAINS WITH SELECTED OR ALTERED MITOTYPES AND METHODS OF MAKING AND USING THE SAME | Final Rejection | Wisconsin Alumni Research Foundation |
| 18058419 | RNA-DIRECTED DNA CLEAVAGE AND GENE EDITING BY CAS9 ENZYME FROM NEISSERIA MENINGITIDIS | Final Rejection | Wisconsin Alumni Research Foundation |
| 18693636 | MRNA REGULON THERAPY FOR THE TREATMENT OF HAPLOINSUFFICIENCY DISORDERS | Non-Final OA | The Johns Hopkins University |
| 15734768 | Methods for Identifying Promoters for Protein Production in Yeast | Final Rejection | BASF SE |
| 16989119 | Large Gene Excision and Insertion | Final Rejection | President and Fellows of Harvard College |
| 16851360 | RNA-Guided Transcriptional Regulation | Non-Final OA | President and Fellows of Harvard College |
| 14319530 | RNA-Guided Transcriptional Regulation | Final Rejection | President and Fellows of Harvard College |
| 17631240 | COMPOSITIONS AND METHODS FOR TREATING ALPHA THALASSEMIA | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17807405 | Compositions, Methods and Systems for the Delivery of Gene Editing Material to Cells | Final Rejection | Massachusetts Institute of Technology |
| 18700992 | PROGRAMMABLE DELIVERY PLATFORMS FOR RNA STRUCTURES | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17040943 | METHOD FOR INCREASING THE EXPRESSION LEVEL OF A NUCLEIC ACID MOLECULE OF INTEREST IN A CELL | Non-Final OA | KWS SAAT SE & Co. KGaA |
| 16625207 | Tropism-Modified Recombinant Viral Particles and Uses Thereof for the Targeted Introduction of Genetic Material into Human Cells | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18270165 | COMPOSITION FOR INHIBITING METASTASIS AND ENHANCING ANTICANCER DRUG SENSITIVITY | Non-Final OA | Korea Advanced Institute of Science and Technology |
| 18573350 | COMPOSITIONS AND METHODS FOR TREATING PGM1 DEFICIENCY | Non-Final OA | UNIVERSITY OF UTAH RESEARCH FOUNDATION |
| 18279282 | POLYNUCLEOTIDE FOR TREATMENT OF NEURODEGENERATIVE DISEASE, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, AND SCREENING METHOD | Non-Final OA | RIKEN |
| 18709175 | COMBINED TARGETING OF STAT3 AND ULKI TO TREAT GLIOBLASTOMA | Non-Final OA | University of Tennessee Research Foundation |
| 17780002 | CONSTRUCTS, COMPOSITIONS AND METHODS THEREOF HAVING IMPROVED GENOME EDITING EFFICIENCY AND SPECIFICITY | Non-Final OA | DANMARKS TEKNISKE UNIVERSITET |
| 18162236 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | Final Rejection | The Trustees of the University of Pennsylvania |
| 18415331 | IN-SITU CRYO-IMMUNE ENGINEERING FOR CANCER IMMUNOTHERAPY | Non-Final OA | University of Maryland, College Park |
| 17915043 | ACTIVITY-DEPENDENT GENE THERAPY FOR NEUROLOGICAL DISORDERS | Non-Final OA | UCL BUSINESS LTD. |
| 18498448 | COMPOSITIONS AND METHODS FOR ENHANCING GENE EXPRESSION | Non-Final OA | Janssen Pharmaceuticals, Inc. |
| 18423377 | 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17782897 | CLINICAL DECISION SUPPORT FOR PERSONALIZED ADAPTIVE PROSTATE CANCER THERAPY | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18565849 | ASSAY FOR QUANTITATIVE ASSESSMENT OF MRNA CAPPING EFFICIENCY | Non-Final OA | TRANSLATE BIO, INC. |
| 18220070 | PREVENTION OR TREATMENT OF WASTING SYNDROME | Non-Final OA | City of Hope |
| 18026128 | ASPOROGENOUS BACTERIA AND USES THEREOF AS A FEED INGREDIENT | Non-Final OA | SUPERBREWED FOOD, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy